Entering text into the input field will update the search result below

Hutchmed starts registration phase for cancer trials after talks with Chinese regulator

Apr. 04, 2023 6:06 AM ETHUTCHMED (China) Limited (HCM) Stock, AZN StockBy: Ravikash Bakolia, SA News Editor
Modern Medicine Research Laboratory: Diverse Team of Multi-Ethnic Young Scientists Passes Samples in Petri Dish. Advanced Lab with High-Tech Equipment, Microbiology Researchers Design, Develop Drugs

gorodenkoff

  • Hutchmed (China) (NASDAQ:HCM) said it consulted China's National Medical Products Administration (NMPA) and reached agreements to start the registration phase enrollments in ongoing trials of drugs HMPL-453 and savolitinib for gastric cancer.
  • A phase 2 trial of HMPL-453 to treat patients with intrahepatic cholangiocarcinoma (IHCC) with

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
AZN
--
HCM
--